prediction
若以該行估算的約2%的坡元融資成本計算,該交易預計可帶來約2.5%的稅前正向利差(positive carry)。
A prediction by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
若以該行估算的約2%的坡元融資成本計算,該交易預計可帶來約2.5%的稅前正向利差(positive carry)。
Discussion
Related claims
若以瑞銀估算的約2%的坡元融資成本計算,該交易預計可帶來約2.5%的稅前正向利差(positive carry)。瑞銀 · predictionA further narrowing of the interest rate differential of about 50 basis points would be enough to drive a rebound in the yen.Neil Parker · predictionThe probability of a one-step (0.25%) rate hike is 85%, bringing the rate to the 4.00% to 4.25% range.بازار · prediction瑞銀預期該交易將對每個基金單位分派(DPU)產生約0.5%的溫和增值效應。瑞銀 · predictionDovish risks could cap the terminal rate below 6%.花旗 · predictionWith yields still near 20-year relative highs, investors can lock in better yields and also capture capital gains from a future rate-cut cycle.郭修誠 · prediction
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀